A recent analysis on the impact of recent foreign reference pricing proposals makes it clear that implementation will slash investment in small and emerging biotechs, chill biopharmaceutical research and development, and ultimately dash the hopes of patients who rely on the industry for new treatments and cures.

The national impact would:

- Reduce the number of medicines developed by small and emerging biotechs by over 90% – resulting in 61 fewer medicines over 10 years.
- Disproportionately impact new treatments in rare diseases, oncology, and neurology.
- Eliminate nearly 200,000 biopharmaceutical industry jobs, and nearly 1 million jobs across the economy.

Impact in New Jersey:

- **71,834** Total Lost Jobs
- **14,288** Lost Biopharma Jobs
- **$19.6 Bil** Lost Economic Output

Imposing shortsighted healthcare policies will undercut vital drug development and lead to fewer jobs and a weaker economy.

Protect New Jersey’s life sciences and biomedical sectors, and the countless constituents waiting for treatments and cures.